Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CRIS Stock Summary
Top 10 Correlated ETFs
CRIS
In the News

Curis's stock rises as analysts see ‘the next Pharmacyclics'
Shares of Curis Inc. CRIS, +4.23% gained nearly 6% premarket on Friday after Truist Securities analysts initiated coverage of the cancer-focused biotech company with a buy rating.

Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Conference Call Participants Yale Jen - Laidlaw & Co. Operator Good morning, and welcome to Curis' Third Quarter 2023 Business Update Call. All participants will be in a listen-only mode.

Curis to Present at Upcoming Healthcare Conferences in September
LEXINGTON, Mass. , Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The H.C.

Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates
Curis (CRIS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023
LEXINGTON, Mass. , July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 3, 2023, after the close of U.S. markets.

Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
Curis (CRIS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.18 per share a year ago.

Curis to Present at Upcoming Healthcare Conferences in April
LEXINGTON, Mass. , April 3, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023.

Curis, Inc. (CRIS) Q4 2022 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer James Dentzer - President and Chief Executive Officer Robert Martell - Head of R&D Conference Call Participants Ed White - H.C. Wainwright Soumit Roy - JonesTrading Yale Jen - Laidlaw & Company Operator Good morning, and welcome to the Curis Fourth Quarter 2022 Business Update Call.

Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates
Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call
LEXINGTON, Mass. , March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it is rescheduling its fourth quarter business update and quarterly investor conference call previously scheduled for Thursday, March 9, 2023 at 4:30 p.m.
CRIS Financial details
CRIS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 6.3 | 6.03 | 4.45 | 2.33 | 2.18 | |
Net income per share | -19.67 | -22.18 | -14.33 | -11.06 | -12.92 | |
Operating cash flow per share | -18.16 | -15.8 | -10.58 | -8.22 | -11.64 | |
Free cash flow per share | -18.21 | -15.82 | -10.86 | -8.22 | -11.73 | |
Cash per share | 14.66 | 12.38 | 69.24 | 25.31 | 18.34 | |
Book value per share | -2.72 | -20.44 | 53.7 | 19.81 | 9.97 | |
Tangible book value per share | -8.14 | -25.85 | 50 | 17.85 | 8.05 | |
Share holders equity per share | -2.72 | -20.44 | 53.7 | 19.81 | 9.97 | |
Interest debt per share | 27.96 | 3.02 | 5.24 | 3.03 | 2.47 | |
Market cap | 1.14M | 2.82M | 19.93M | 21.79M | 2.57M | |
Enterprise value | 12.99M | -12.44M | -102.02M | -13.18M | -10.35M | |
P/E ratio | -0.04 | -0.08 | -0.57 | -0.43 | -0.04 | |
Price to sales ratio | 0.11 | 0.28 | 1.84 | 2.05 | 0.25 | |
POCF ratio | -0.04 | -0.11 | -0.77 | -0.58 | -0.05 | |
PFCF ratio | -0.04 | -0.11 | -0.75 | -0.58 | -0.05 | |
P/B Ratio | -0.25 | -0.08 | 0.15 | 0.24 | 0.06 | |
PTB ratio | -0.25 | -0.08 | 0.15 | 0.24 | 0.06 | |
EV to sales | 1.25 | -1.24 | -9.42 | -1.24 | -1.02 | |
Enterprise value over EBITDA | -0.45 | 0.52 | 4.11 | 0.32 | 0.2 | |
EV to operating cash flow | -0.43 | 0.47 | 3.96 | 0.35 | 0.19 | |
EV to free cash flow | -0.43 | 0.47 | 3.86 | 0.35 | 0.19 | |
Earnings yield | -28.51 | -13.05 | -1.75 | -2.32 | -23.49 | |
Free cash flow yield | -26.39 | -9.31 | -1.33 | -1.73 | -21.32 | |
Debt to equity | -9.42 | 0 | 0.06 | 0.1 | 0.14 | |
Debt to assets | 1.13 | 0 | 0.04 | 0.06 | 0.06 | |
Net debt to EBITDA | -0.41 | 0.64 | 4.91 | 0.85 | 0.24 | |
Current ratio | 4.25 | 3.78 | 12.84 | 8.08 | 6.96 | |
Interest coverage | -7.47 | -5.03 | -4.89 | -9.41 | -11.11 | |
Income quality | 0.92 | 0.82 | 0.86 | 0.83 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.42 | 1.16 | 1.12 | 1.62 | 1.93 | |
Research and developement to revenue | 2.34 | 2.23 | 2.13 | 3.28 | 4.26 | |
Intangibles to total assets | 0.24 | 0.26 | 0.04 | 0.06 | 0.08 | |
Capex to operating cash flow | 0 | 0 | 0.03 | 0 | 0.01 | |
Capex to revenue | -0.01 | 0 | -0.06 | 0 | -0.04 | |
Capex to depreciation | -0.48 | -0.33 | -4.7 | 0 | -1.79 | |
Stock based compensation to revenue | 0.38 | 0.27 | 0.25 | 0.5 | 0.66 | |
Graham number | 34.67 | 101.01 | 131.59 | 70.22 | 53.83 | |
ROIC | -0.79 | 0.83 | -0.2 | -0.45 | -0.99 | |
Return on tangible assets | -1.15 | -1.41 | -0.18 | -0.33 | -0.6 | |
Graham Net | -9.58 | -27.78 | 39.81 | 9.92 | 5.16 | |
Working capital | 20.76M | 18.22M | 172.36M | 126M | 76.42M | |
Tangible asset value | -13.48M | -42.89M | 121.69M | 81.73M | 37.57M | |
Net current asset value | -14.73M | -44.26M | 113.23M | 72.2M | 26.94M | |
Invested capital | -9.42 | 0 | 0.06 | 0.1 | 0.14 | |
Average receivables | 2.97M | 3.05M | 3.14M | 3.13M | 3.1M | |
Average payables | 4.17M | 3.69M | 4.32M | 5.29M | 4.81M | |
Average inventory | -413.5K | -460.5K | -246.5K | -1.47M | -2.71M | |
Days sales outstanding | 100.25 | 118.36 | 102.51 | 110.5 | 106.86 | |
Days payables outstanding | 1.89K | 3.24K | 2.85K | 4.39K | 4.53K | |
Days of inventory on hand | -536.15 | -68.21 | -272.72 | -1.74K | -4.1K | |
Receivables turnover | 3.64 | 3.08 | 3.56 | 3.3 | 3.42 | |
Payables turnover | 0.19 | 0.11 | 0.13 | 0.08 | 0.08 | |
Inventory turnover | -0.68 | -5.35 | -1.34 | -0.21 | -0.09 | |
ROE | 7.25 | 1.09 | -0.27 | -0.56 | -1.3 | |
Capex per share | -0.05 | -0.02 | -0.28 | 0 | -0.09 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.6 | 0.6 | 0.48 | 0.45 | 0.5 | |
Net income per share | -2.98 | -2.58 | -2.38 | -2.47 | -2.13 | |
Operating cash flow per share | -2.8 | -2.54 | -2.53 | -1.63 | 0.29 | |
Free cash flow per share | -2.81 | -2.54 | -2.53 | -1.63 | 0.29 | |
Cash per share | 21.04 | 17.76 | 14.85 | 13.13 | 11.97 | |
Book value per share | 11.89 | 9.66 | 7.57 | 5.42 | 5.17 | |
Tangible book value per share | 9.97 | 7.79 | 5.72 | 3.57 | 3.6 | |
Share holders equity per share | 11.89 | 9.66 | 7.57 | 5.42 | 5.17 | |
Interest debt per share | 1.11 | 1.74 | 1.26 | 0.83 | 0.76 | |
Market cap | 3.28M | 2.65M | 2.9M | 4.01M | 37.7M | |
Enterprise value | -22.37M | -10.27M | -25.12M | -12.43M | 16.32M | |
P/E ratio | -0.06 | -0.05 | -0.06 | -0.08 | -0.77 | |
Price to sales ratio | 1.16 | 0.92 | 1.26 | 1.83 | 13.31 | |
POCF ratio | -0.25 | -0.22 | -0.24 | -0.51 | 23.09 | |
PFCF ratio | -0.25 | -0.22 | -0.24 | -0.51 | 23.09 | |
P/B Ratio | 0.06 | 0.06 | 0.08 | 0.15 | 1.27 | |
PTB ratio | 0.06 | 0.06 | 0.08 | 0.15 | 1.27 | |
EV to sales | -7.92 | -3.56 | -10.94 | -5.66 | 5.76 | |
Enterprise value over EBITDA | 1.83 | 1 | 2.16 | 1.1 | -1.32 | |
EV to operating cash flow | 1.7 | 0.84 | 2.06 | 1.58 | 10 | |
EV to free cash flow | 1.7 | 0.84 | 2.06 | 1.58 | 10 | |
Earnings yield | -4.26 | -4.69 | -3.96 | -2.98 | -0.32 | |
Free cash flow yield | -4.01 | -4.63 | -4.21 | -1.96 | 0.04 | |
Debt to equity | 0.08 | 0.14 | 0.17 | 0.13 | 0.15 | |
Debt to assets | 0.03 | 0.06 | 0.07 | 0.04 | 0.05 | |
Net debt to EBITDA | 2.1 | 1.26 | 2.41 | 1.46 | 1.73 | |
Current ratio | 7.69 | 6.96 | 7.07 | 7.01 | 6.19 | |
Interest coverage | -12.32 | -6.19 | 170.99 | -19.03 | 0 | |
Income quality | 0.99 | 1.08 | 1.06 | 0.66 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.61 | 1.5 | 2.07 | 1.93 | 1.68 | |
Research and developement to revenue | 3.83 | 3.02 | 3.98 | 4.56 | 3.66 | |
Intangibles to total assets | 0.07 | 0.08 | 0.1 | 0.11 | 0.1 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.02 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.85 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.47 | 0.6 | 0.61 | 0.65 | 0.58 | |
Graham number | 28.24 | 23.67 | 20.13 | 17.38 | 15.74 | |
ROIC | -0.21 | -0.2 | -0.25 | -0.39 | -0.33 | |
Return on tangible assets | -0.12 | -0.12 | -0.13 | -0.16 | -0.15 | |
Graham Net | 7.2 | 5 | 2.88 | 1.49 | 1.84 | |
Working capital | 91.98M | 76.42M | 64.15M | 58.17M | 64.65M | |
Tangible asset value | 46.76M | 37.57M | 27.61M | 17.24M | 20.61M | |
Net current asset value | 38.61M | 26.94M | 16.75M | 9.77M | 16.71M | |
Invested capital | 0.08 | 0.14 | 0.17 | 0.13 | 0.15 | |
Average receivables | 2.64M | 2.93M | 2.64M | 2.35M | 2.62M | |
Average payables | 5.63M | 4.47M | 2.92M | 2.66M | 3.95M | |
Average inventory | 0 | -1.44M | -3.09M | -1.65M | 272K | |
Days sales outstanding | 91.94 | 92.74 | 90.67 | 97.74 | 90.48 | |
Days payables outstanding | 8.36K | 4.05K | 9.91K | 3.27K | 7.83K | |
Days of inventory on hand | 0 | -3.66K | -12.38K | 0 | 816 | |
Receivables turnover | 0.98 | 0.97 | 0.99 | 0.92 | 0.99 | |
Payables turnover | 0.01 | 0.02 | 0.01 | 0.03 | 0.01 | |
Inventory turnover | 0 | -0.02 | -0.01 | 0 | 0.11 | |
ROE | -0.25 | -0.27 | -0.31 | -0.46 | -0.41 | |
Capex per share | -0.01 | 0 | 0 | 0 | 0 |
CRIS Frequently Asked Questions
What is Curis, Inc. stock symbol ?
Curis, Inc. is a US stock , located in Lexington of Ma and trading under the symbol CRIS
What is Curis, Inc. stock quote today ?
Curis, Inc. stock price is $11.54 today.
Is Curis, Inc. stock public?
Yes, Curis, Inc. is a publicly traded company.